Thierry André

64.2k total citations · 16 hit papers
720 papers, 37.1k citations indexed

About

Thierry André is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thierry André has authored 720 papers receiving a total of 37.1k indexed citations (citations by other indexed papers that have themselves been cited), including 564 papers in Oncology, 220 papers in Pathology and Forensic Medicine and 220 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thierry André's work include Colorectal Cancer Treatments and Studies (466 papers), Genetic factors in colorectal cancer (213 papers) and Cancer Treatment and Pharmacology (144 papers). Thierry André is often cited by papers focused on Colorectal Cancer Treatments and Studies (466 papers), Genetic factors in colorectal cancer (213 papers) and Cancer Treatment and Pharmacology (144 papers). Thierry André collaborates with scholars based in France, United States and Belgium. Thierry André's co-authors include Aimery de Gramont, Christophe Louvet, Josep Tabernero, Christophe Tournigand, Eric Van Cutsem, Tamas Hickish, C. Boni, C. Topham, Matilde Navarro and Gérard Lledo and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Thierry André

669 papers receiving 36.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

2004 2.7k citations Thierry André, Aimery de Gramont et al. profile →
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

2003 2.3k citations Christophe Tournigand, Thierry André et al. Journal of Clinical Oncology profile →
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

2012 2.1k citations Eric Van Cutsem, Alberto Sobrero et al. profile →
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

2017 2.0k citations Michael J. Overman, Ray McDermott et al. profile →
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

2009 1.6k citations Thierry André, Aimery de Gramont et al. Journal of Clinical Oncology profile →
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

2018 1.4k citations Michael J. Overman, Sara Lonardi et al. Journal of Clinical Oncology profile →
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

2008 1.1k citations Astrid Lièvre, Jean‐Baptiste Bachet et al. Journal of Clinical Oncology profile →
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

2012 829 citations Jaafar Bennouna, Pia Österlund et al. profile →
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

2005 760 citations Christophe Louvet, Gérard Lledo et al. Journal of Clinical Oncology profile →
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

2010 755 citations Marc Peeters, Timothy Price et al. Journal of Clinical Oncology profile →
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

2016 685 citations Pascal Artru, Olivier Bouché et al. profile →
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

2006 583 citations Christophe Tournigand, Andrés Cervantes et al. Journal of Clinical Oncology profile →
Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

2005 520 citations Marc Buyse, Thierry André et al. Journal of Clinical Oncology profile →
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

2022 501 citations Luis A. Díaz, Kai‐Keen Shiu et al. profile →
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

2022 220 citations Thierry André, David Tougeron et al. Journal of Clinical Oncology profile →
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

2022 154 citations Thierry André, Sara Lonardi et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Thierry André

Since Specialization

Citations

This map shows the geographic impact of Thierry André's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry André with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry André more than expected).

Fields of papers citing papers by Thierry André

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thierry André. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry André. The network helps show where Thierry André may publish in the future.

Co-authorship network of co-authors of Thierry André

This figure shows the co-authorship network connecting the top 25 collaborators of Thierry André. A scholar is included among the top collaborators of Thierry André based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thierry André. Thierry André is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The METACER national cohort study of brain metastases in gastrointestinal cancers prospectively establishes prognostic factors 2025 ·Journal of Neuro-Oncology ·Violaine Randrian, Fabienne Portales, Olivier Bouché, Simon Thézenas, Benoist Chibaudel, May Mabro, Éric Terrebonne, Claire Garnier-Tixidré, C. Louvet, Thierry André, (unknown), Olivier Dubreuil, Gauthier Bouche, Marc Ychou, David Tougeron	0
2	Preservation of Wagashi Cheese with Lippia multiflora Leaf Decoction: Effects on Microbiological, Nutritional and Sensory Quality 2025 ·Asian Journal of Dairy and Food Research ·(unknown), (unknown), (unknown), Thierry André	0
3	Influence of a cutting fluid on the surface integrity and fatigue strength of 42CrMo4 drilled parts. 2024 ·Procedia CIRP ·(unknown), (unknown), (unknown), Thierry André, (unknown), (unknown), (unknown), J. Rech	0
4	Experimental study of residual stress profiles evolution in longitudinal turning with flank wear progress 2024 ·Procedia CIRP ·Sangil Han, (unknown), (unknown), (unknown), Thierry André, Frédéric Valiorgue, J. Rech	2
5	Experimental study of residual stress profiles evolution in face turning with flank wear progress 2024 ·Procedia CIRP ·Sangil Han, (unknown), (unknown), (unknown), Thierry André, Frédéric Valiorgue, (unknown)	1
6	Tolérance et efficacité des inhibiteurs de points de contrôle immunitaire en monothérapie chez les patients âgés 2023 ·Bulletin du Cancer ·(unknown), Daniel López‐Trabada, Judith P. Feldman, Thierry André, Romain Cohen	0
7	651P DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study 2023 ·Annals of Oncology ·Christophe Borg, V. Vendrely, (unknown), Thierry André, (unknown), (unknown), Simon Pernot, O. Bouché, Jérôme Desrame, Christelle de la Fouchardière, Denis Smith, François Ghiringhelli, Angélique Vienot, Éric François, Julien Taı̈eb, Karine Le Malicot, Déwi Vernerey, Aurélia Meurisse, Stéfano Kim	1
8	LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study 2023 ·Annals of Oncology ·(unknown), Thierry André, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, C.J.A. Punt, Denis Smith, Rocio García‐Carbonero, Julia Alcaide, Peter Gibbs, Christelle de la Fouchardière, Fernando Rivera, (unknown), Dung T. Le, Takayuki Yoshino, Yu Zuo, (unknown), David E. Adelberg, Luis A. Díaz	12
9	Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer 2023 ·ESMO Open ·Cornelis J.A. Punt, Volker Heinemann, Tim Maughan, Chiara Cremolini, Eric Van Cutsem, Ray McDermott, (unknown), Thierry André, Pia Österlund, Arco J. Teske, Per Pfeiffer	4
10	Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study breakdown → 2022 ·Journal of Clinical Oncology ·Thierry André, David Tougeron, Guillaume Piessen, Christelle de la Fouchardière, Christophe Louvet, Antoine Adenis, Marine Jary, Christophe Tournigand, Thomas Aparicio, Jérôme Desrame, Astrid Lièvre, Marie‐Line Garcia‐Larnicol, T. Pudlarz, Romain Cohen, (unknown), Dewi Vernerey, Julie Henriques, Jérémie H. Lefèvre, Magali Svrcek	220
11	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial 2021 ·Clinical Cancer Research ·Julien Taı̈eb, Valérie Taly, Julie Henriques, (unknown), Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Christophe Louvet, Céline Lepère, May Mabro, Joëlle Egreteau, Olivier Bouché, Claire Mulot, (unknown), Kariman Chaba, Thibault Mazard, Aimery de Gramont, Déwi Vernerey, Thierry André, Pierre Laurent‐Puig	71
12	O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer 2021 ·Annals of Oncology ·Thierry André, Kai‐Keen Shiu, (unknown), Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Julia Alcaide, Peter Gibbs, Christelle de la Fouchardière, F. Rivera Herrero, Elena Élez, Johanna C. Bendell, Dung T. Le, Takayuki Yoshino, (unknown), David R. Fogelman, Patricia Marinello, Luis A. Díaz	1
13	Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status 2018 ·Clinical Cancer Research ·Paul Mésange, (unknown), Nathalie Ferrand, Michèle Sabbah, Alexandre E. Escargueil, Ariel Savina, Benoist Chibaudel, Christophe Tournigand, Thierry André, Aimery de Gramont, Annette K. Larsen	14
14	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer breakdown → 2018 ·Journal of Clinical Oncology ·Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A. Moss, Jean-Marie Ledeine, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André	1429
15	Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer 2013 ·Clinical Cancer Research ·Marc Peeters, Kelly S. Oliner, Alex Parker, Salvatore Siena, Eric Van Cutsem, Jing Huang, Yves Humblet, Jean–Luc Van Laethem, Thierry André, Jeffrey S. Wiezorek, David Reese, Scott D. Patterson	185
16	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer breakdown → 2010 ·Journal of Clinical Oncology ·Marc Peeters, Timothy Price, Andrés Cervantes, Alberto Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew Strickland, G. Wilson, Tudor–Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Valentina Tzekova, Simon Collins, Kelly S. Oliner, Alan Rong, Jennifer Gansert	755
17	Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study 2009 ·Journal of Clinical Oncology ·Benoist Chibaudel, Frédérique Maindrault‐Gœbel, Gérard Lledo, Laurent Mineur, Thierry André, (unknown), May Mabro, Pascal Artru, Élisabeth Carola, M. Flesch, Olivier Dupuis, Philippe Colin, Annette K. Larsen, Pauline Afchain, Christophe Tournigand, Christophe Louvet, Aimery de Gramont	262
18	KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab breakdown → 2008 ·Journal of Clinical Oncology ·Astrid Lièvre, Jean‐Baptiste Bachet, Valérie Boige, Anne Cayre, Delphine Le Corre, Emmanuel Buc, Marc Ychou, Olivier Bouché, Bruno Landi, Christophe Louvet, Thierry André, Frédéric Bibeau, Marie-Danièle Diébold, Philippe Rougier, Michel Ducreux, Gorana Tomasic, Jean‐François Emile, Frédérique Penault–Llorca, Pierre Laurent‐Puig	1141
19	FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study breakdown → 2003 ·Journal of Clinical Oncology ·Christophe Tournigand, Thierry André, Emmanuel Achille, Gérard Lledo, (unknown), D. Méry-Mignard, Emmanuel Quinaux, C. Couteau, Marc Buyse, G. Ganem, Bruno Landi, Philippe Colin, Christophe Louvet, Aimery de Gramont	2290
20	Vegf, vegf-B, vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa 2000 ·International Journal of Cancer ·Thierry André, Larissa Kotelevets, Jean‐Christophe Vaillant, (unknown), (unknown), Sophie Prévôt, R Parc, Christian Gespach, Eric Chastre	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact